INTERVIEW WITH PROFESSOR EVANDRO DE AZAMBUJA
IN-HOSPITAL MORTALITY OF PATIENTS WITH COVID-19 WITH PRIOR OR CURRENT SOLID CANCER VERSUS THOSE WITHOUT CANCER
In a large nationwide analysis, Professor Evandro de Azambuja and colleagues assessed the impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19 following the first wave of the pandemic in Belgium… Read more
INTERVIEW WITH PROFESSOR TIMOTHY DEVOS
DAWN-PLASMA TRIAL AND THE USE OF CONVALESCENT PLASMA FOR COVID-19
The COVID-19 pandemic has imposed an enormous burden on health care systems around the world. In the past, the administration of convalescent plasma of persons having recovered from SARS and severe influenza to patients suffering from active disease showed promising effects on mortality and appeared safe. Whether or not this also holds true for the novel SARS-CoV-2 virus is currently unknown… Read more
INTERVIEW WITH PROFESSOR MARK DE RIDDER
THE IMPACT OF COVID-19 ON RADIOTHERAPY ACTIVITY
In a national survey the results showed a drop in radiotherapy activity in Belgian hospitals to 87% at its lowest point. However, in the UZ Brussel, they remained at full capacity and adapted to the pandemic situation early on. In this interview professor Mark de Ridder explains how they achieved this… Read more
BCG & COVID-19
MYCOBACTERIUM BCG PROTECTS NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS FROM SEVERE COVID-19 PROGRESSION
The Mycobacterium bovis Bacillus Calmette-Guérin (BCG) is an active compound for tuberculosis that has also been described to protect against other respiratory infections. BCG is being used as a standard of care in patients with intermediate-high risk, non-muscle invasive bladder cancer (NMIBC). A new cohort study investigated the role of BCG instillations in the incidence and mortality of COVID-19 in NMIBC patients… Read more
Top
